Synapse - Glenn Heller

Results (400)

Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC)

Meeting Abstract

Morris, M. J.; Heller, G.; Bryce, A. H.; Armstrong, A. J.; Beltran, H.; Hahn, O. M.; McGary, E. C.; Mehan, P. T.; Goldkorn, A.; Roth, B. J.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

CALGB 90203 (Alliance): Radical prostatectomy (RP) with or without neoadjuvant chemohormonal therapy (CHT) in men with clinically localized, high-risk prostate cancer (CLHRPC)

Meeting Abstract

Eastham, J. A.; Heller, G.; Halabi, S.; Monk, P.; Clinton, S. K.; Szmulewitz, R. Z.; Coleman, J.; Gleave, M.; Evans, C. P.; Hillman, D. W.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Assessment of circulating tumor cell number as a transitional surrogate endpoint for survival in phase II trials for metastatic castration-resistant prostate cancer

Meeting Abstract

Scher, H. I.; McCormack, R. T.; Molina, A.; Smith, M. R.; Dreicer, R.; Saad, F.; De Wit, R.; Fizazi, K.; Aftab, D. T.; Limon, A.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Clinicopathologic and genomic characterization of parenchymal brain metastases (BM) in prostate cancer (PCa)

Meeting Abstract

Mota, J. M. S. C.; Teo, M. Y.; Knezevic, A.; Bambury, R. M.; Hatzoglou, V.; Autio, K. A.; Abida, W.; Gopalan, A.; Fine, S.; Danila, D. C.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Genomic correlates of clinical outcome in advanced prostate cancer

Journal Article

Abida, W.; Cyrta, J.; Heller, G.; Prandi, D.; Armenia, J.; Coleman, I.; Cieslik, M.; Benelli, M.; Robinson, D.; Van Allen, E. M.; more...
Proceedings of the National Academy of Sciences of the United States of America (2019)

Fulltext@MSK | Save

Phase 2, randomized, 3-arm study of abiraterone acetate and prednisone (AAP), AAP plus degarelix (AAP plus D), and degarelix (D) alone for patients (pts) with biochemically-recurrent prostate cancer (PC) following radical prostatectomy (RP)

Meeting Abstract

Autio, K. A.; Antonarakis, E. S.; Mayer, T. M.; Vaishampayan, U. N.; Shevrin, D. H.; Harrison, M. R.; Tagawa, S. T.; Milowsky, M. I.; Graff, J. N.; Beer, T. M.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

A phase 3 study of androgen annihilation in high-risk biochemically relapsed prostate cancer: An Alliance Foundation trial (AFT-19)

Meeting Abstract

Aggarwal, R. R.; Eggener, S. E.; Chen, R. C.; Heller, G.; Patnaik, A.; Xiao, H.; Weckstein, D.; Mohler, J.; Watson, M.; Taplin, M. E.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Validation of nuclear-localized AR-V7 on circulating tumor cells (CTC) as a treatment-selection biomarker for managing metastatic castration-resistant prostate cancer (mCRPC)

Meeting Abstract

Scher, H. I.; Graf, R. P.; Schreiber, N. A.; Winquist, E.; McLaughlin, B.; Lu, D.; Orr, S.; Fleisher, M.; Lowes, L.; Anderson, A. K. L.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Assessment of the validity of nuclear-localized androgen receptor splice variant 7 in circulating tumor cells as a predictive biomarker for castration-resistant prostate cancer

Journal Article

Scher, H. I.; Graf, R. P.; Schreiber, N. A.; Jayaram, A.; Winquist, E.; McLaughlin, B.; Lu, D.; Fleisher, M.; Orr, S.; Lowes, L.; more...
JAMA Oncology (2018)

Fulltext@MSK | Save

Primary T cells from cutaneous T-cell lymphoma skin explants display an exhausted immune checkpoint profile

Journal Article

Querfeld, C.; Leung, S.; Myskowski, P. L.; Curran, S. A.; Goldman, D. A.; Heller, G.; Wu, X.; Kil, S. H.; Sharma, S.; Finn, K. J.; more...
Cancer Immunology Research (2018)

Fulltext@MSK | Save